Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...

BigHat Biosciences, a biotechnology company, has entered a strategic collaboration with Eli Lilly and Company.

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

No sooner did Eli Lilly (NYSE: LLY)’s oral diabetes candidate orforglipron make history Thursday as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to ace a Phase ...

Verzenio has multiple approvals granted by the Food and Drug Administration (FDA), which widens Lilly's opportunity in the oncology market. Another opportunity that I'm highly optimistic about is ...

A new daily weight-loss pill could be just as effective as the popular injectables that help patients lower their blood sugar and lose unwanted weight. "I think we're really at the beginning of a ...

"Be mindful about what you're sharing, because once it's online, it's online forever," says Lilly Sabri. The fitness influencer, who has six million followers on YouTube, has urged fans to heed ...